| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10962980 | Vaccine | 2015 | 8 Pages |
Abstract
NBP607, a novel CCIV, showed excellent immunogenicity that lasted â¥6 months after vaccination and had tolerable safety profiles. In particular, NBP607 was more immunogenic against influenza B compared to the control, an egg-based subunit vaccine.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Joon Young Song, Hee Jin Cheong, Jacob Lee, Heung Jeong Woo, Seong-Heon Wie, Jin-Soo Lee, Shin Woo Kim, Ji Yun Noh, Won Suk Choi, Hun Kim, Kyung-Ho Kim, Woo Joo Kim,